<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cyclosporine and tacrolimus nephrotoxicity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cyclosporine and tacrolimus nephrotoxicity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cyclosporine and tacrolimus nephrotoxicity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen Hardinger, PharmD, BCPS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel C Brennan, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 04, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients treated with the calcineurin inhibitors (CNIs)
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         are at high risk of developing kidney injury [
         <a href="#rid1">
          1
         </a>
         ]. CNI nephrotoxicity is manifested either as acute kidney injury (AKI), which is largely reversible after reducing the dose, or as chronic progressive kidney disease, which is usually irreversible [
         <a href="#rid2">
          2-5
         </a>
         ]. Other kidney effects of the CNIs include tubular dysfunction and, rarely, a thrombotic microangiopathy (TMA) that can lead to acute kidney allograft loss [
         <a href="#rid2">
          2
         </a>
         ]. Most data on CNI nephrotoxicity pertain to cyclosporine since it has been used for a much longer time. However, a similar pattern of kidney injury from cyclosporine is seen with the use of tacrolimus, thereby suggesting a drug class effect. CNI toxicity is seen most frequently in kidney transplant recipients, but it has been reported in other populations including hematopoietic cell transplant [
         <a href="#rid6">
          6
         </a>
         ] and non-kidney solid organ transplant [
         <a href="#rid7">
          7-10
         </a>
         ] recipients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7197.html" rel="external">
          "Kidney disease following hematopoietic cell transplantation", section on 'Calcineurin inhibitor toxicity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7331.html" rel="external">
          "Kidney function and non-kidney solid organ transplantation", section on 'Chronic kidney disease after non-kidney organ transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         This topic will review the acute and chronic nephrotoxicity of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         as well as strategies to prevent chronic CNI nephrotoxicity. The pharmacology of CNIs, including a discussion of the nonrenal side effects of cyclosporine and tacrolimus, is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H477046481">
         <span class="h1">
          INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the earliest clinical kidney transplant trials using
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , a high incidence of oliguric acute kidney injury (AKI) and primary nonfunction (ie, acute calcineurin inhibitor [CNI] nephrotoxicity) was observed; the risk was greatest with prolonged ischemia time of the donated kidney prior to transplantation [
         <a href="#rid11">
          11
         </a>
         ]. Subsequent trials using lower doses of cyclosporine showed that these problems were dose related, although there was considerable variability in the incidence of AKI in various centers.
        </p>
        <p>
         Support for the hypothesis of chronic CNI nephrotoxicity comes most directly from non-kidney transplant patients and patients with autoimmune diseases in whom the nephrotoxic potential of CNIs can be evaluated in the absence of coexisting acute or chronic rejection of a kidney allograft. These patients have a 35 to 45 percent reduction in glomerular filtration rate (GFR) compared with patients not treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         . This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7331.html" rel="external">
          "Kidney function and non-kidney solid organ transplantation"
         </a>
         .)
        </p>
        <p>
         The best data on the overall incidence of chronic kidney disease (CKD) with CNIs come from a cohort study of non-kidney transplant recipients (mostly liver, heart, and lung) in the United States [
         <a href="#rid12">
          12
         </a>
         ].
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         was given to 60 percent and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         to 28 percent. At a median follow-up of 36 months, 17 percent developed CKD (defined as an estimated GFR [eGFR] ≤29 mL/min/1.73 m
         <sup>
          2
         </sup>
         ). The risk continued to increase over time with all kinds of transplants and, at 5 years, ranged from 7 to 21 percent  (
         <a class="graphic graphic_figure graphicRef54972" href="/z/d/graphic/54972.html" rel="external">
          figure 1
         </a>
         ). These patients had a 4.6-fold increase in the risk of death compared with those without CKD. Risk factors for CKD included calcineurin therapy, older age, lower pretransplant GFR, female sex, postoperative AKI, baseline diabetes and hypertension, and hepatitis C virus infection. (See
         <a class="medical medical_review" href="/z/d/html/7331.html" rel="external">
          "Kidney function and non-kidney solid organ transplantation"
         </a>
         .)
        </p>
        <p>
         Some patients with CKD, 29 percent in the above report, eventually progress to end-stage kidney disease (ESKD) and require kidney replacement therapy [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3463063764">
         <span class="h2">
          Cyclosporine versus tacrolimus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute and chronic nephrotoxicity are generally similar with both
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ]. However, tacrolimus has less nephrotoxicity with lower doses without compromising overall outcomes [
         <a href="#rid16">
          16-18
         </a>
         ]. This was best shown in the Efficacy Limiting Toxicity Elimination-Symphony (ELITE-Symphony) study [
         <a href="#rid16">
          16
         </a>
         ]. In this trial, 1645 kidney transplant recipients were randomly assigned to one of four immunosuppressive arms: conventional-dose cyclosporine, glucocorticoids, and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil or daclizumab induction therapy, mycophenolate mofetil, and glucocorticoids with either low-dose cyclosporine (target trough level of 50 to 100 ng/mL), low-dose
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         (target trough level of 4 to 8 ng/mL), or low-dose tacrolimus (target trough level of 3 to 7 ng/mL). At one year, the low-dose tacrolimus group had the highest mean calculated GFR compared with the other three groups (65 versus 57 to 60 mL/min). The tacrolimus-based regimen was also associated with the lowest allograft rejection and highest allograft survival rates. At three years, the low-dose tacrolimus group continued to have the highest mean calculated GFR (69 mL/min versus 64 to 66 mL/min) [
         <a href="#rid19">
          19
         </a>
         ]. Further discussion of this study is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">
          "Kidney transplantation in adults: Maintenance immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
         Long-term trials comparing
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         in liver transplant recipients found a similar incidence of early AKI and late hypertension, while late kidney function impairment was more prevalent with tacrolimus [
         <a href="#rid20">
          20-22
         </a>
         ]. By contrast, the registry data from almost 70,000 non-kidney solid organ transplant recipients found that tacrolimus was associated with less nephrotoxicity in liver transplants and similar nephrotoxicity in other transplants [
         <a href="#rid12">
          12
         </a>
         ]. Another retrospective study of liver transplant recipients also found that tacrolimus was associated with relatively better kidney function [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         However, these data are confounded by evidence that CKD in non-kidney transplant patients is not necessarily due to CNI therapy alone. In one kidney biopsy study of 26 liver transplant recipients, for example, CKD was due to four different pathogenic processes: chronic CNI therapy, diabetic nephropathy, thrombotic microangiopathy (TMA) due to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         /
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         and/or alfa-interferon, and tubular disease due to hydroxyethyl starch [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1408042114">
         <span class="h1">
          RISK FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several factors may contribute to the risk of calcineurin inhibitor (CNI) nephrotoxicity [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High doses of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid24">
          24,25
         </a>
         ] or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid26">
          26
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age of donated kidney [
         <a href="#rid27">
          27
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concomitant use of nephrotoxic drugs, particularly nonsteroidal antiinflammatory drugs (NSAIDs) [
         <a href="#rid28">
          28,29
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Salt depletion and diuretic use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs that inhibit cytochrome P-450 3A4/5 (CYP3A4/5), thereby increasing exposure to CNI metabolites  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drugs that inhibit P-glycoprotein-mediated efflux of CNIs from tubular epithelial cells, thereby increasing local renal exposure to CNIs  (
         <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic polymorphisms in the genes encoding CYP3A4/5
         <em>
          (CYP3A4/5
         </em>
         )
         <em>
         </em>
         and P-glycoprotein (
         <em>
          ABCB1
         </em>
         ) [
         <a href="#rid30">
          30-35
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recipient arteriosclerosis in a zero-time allograft biopsy [
         <a href="#rid36">
          36
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2463763840">
         <span class="h1">
          PATHOGENESIS AND PATHOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3496591036">
         <span class="h2">
          Acute calcineurin inhibitor nephrotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most data in this field pertain to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , although the effects of
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         are thought to be similar. Studies have demonstrated that cyclosporine causes vasoconstriction of the afferent and efferent glomerular arterioles [
         <a href="#rid37">
          37
         </a>
         ] and reductions in renal blood flow and glomerular filtration rate (GFR). The exact mechanism of vasoconstriction is unclear, but there appears to be substantial impairment of endothelial cell function, leading to reduced production of vasodilators (prostaglandins and nitric oxide) and enhanced release of vasoconstrictors (endothelin and thromboxane) [
         <a href="#rid37">
          37-40
         </a>
         ]. Increased sympathetic tone also may be present [
         <a href="#rid41">
          41
         </a>
         ], although renal vasoconstriction occurs even in denervated kidneys. In addition, transforming growth factor (TGF)-beta-1, endothelin-1, and the production of reactive oxygen and nitrogen species have also been implicated [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Kidney biopsy typically reveals an acute arteriolopathy and tubular vacuolization. Rarely, vascular lesions similar to those in the hemolytic uremic syndrome (HUS) are seen.
        </p>
        <p>
         There may also be an intrinsic kidney susceptibility to cyclosporine-induced renal vasoconstriction. Experimental support for this hypothesis is derived from a study examining the effect of raising the
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         dose in eight pairs of stable, unrelated kidney transplant recipients who had received a deceased-donor kidney from the same donor [
         <a href="#rid42">
          42
         </a>
         ]. Seven of the eight pairs showed a parallel response to increasing the cyclosporine dose (four pairs showed an elevation in the plasma creatinine concentration, while three pairs showed no change).
        </p>
        <p>
         The increase in renal vascular tone induced by
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         may not attenuate with time. Maintenance cyclosporine therapy is associated with transient reductions in renal plasma flow and GFR, which correlate both with dose and with peak cyclosporine levels reached two to four hours after the oral dose [
         <a href="#rid39">
          39
         </a>
         ]. These functional abnormalities are also associated with increased urinary excretion of endothelin, which decreases when trough drug levels are reached. Studies with an endothelin receptor antagonist suggest that endothelin mediates cyclosporine-induced afferent arteriolar constriction, an effect that will lower the intraglomerular pressure and the GFR [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Administration of a calcium channel blocker can prevent the renal vasoconstriction, although not the rise in endothelin excretion [
         <a href="#rid39">
          39
         </a>
         ]. This observation constitutes part of the rationale for the use of calcium channel blockers to treat hypertension in cyclosporine- and tacrolimus-treated transplant recipients. The role of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         in the elevation of blood pressure is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">
          "Hypertension after kidney transplantation"
         </a>
         .)
        </p>
        <p>
         The increase in vascular resistance may therefore be reflected clinically by an elevated plasma creatinine concentration and hypertension [
         <a href="#rid2">
          2,41,43
         </a>
         ]. Cyclosporine-induced renal vasoconstriction can cause delayed recovery from early AKI and, in severe cases, primary nonfunction. These complications are most likely to occur with prolonged ischemia time and high
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         doses [
         <a href="#rid11">
          11
         </a>
         ]; however, even patients with therapeutic trough levels may show signs of nephrotoxicity. (See
         <a class="local">
          'Acute reversible kidney injury'
         </a>
         below.)
        </p>
        <p>
         It is also possible that repeated episodes of kidney ischemia contribute to the development of chronic
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         nephrotoxicity described below (see
         <a class="local">
          'Chronic calcineurin inhibitor nephrotoxicity'
         </a>
         below). The continued release of endothelin after administration of a calcium channel blocker suggests that vascular injury may still be occurring. Thus, short-term prevention of renal vasoconstriction, possibly due to limiting endothelin-induced calcium entry into vascular smooth muscle cells, may not necessarily be associated with long-term protection against vascular disease [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3142674030">
         <span class="h2">
          Chronic calcineurin inhibitor nephrotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic calcineurin inhibitor (CNI) nephrotoxicity is manifested by kidney function impairment due to glomerular and vascular disease, abnormalities in tubular function, and an increase in blood pressure [
         <a href="#rid2">
          2,15
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Chronic kidney disease'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Electrolyte and acid-base disturbances'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Hyperuricemia and gout'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">
          "Hypertension after kidney transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Kidney biopsy reveals an obliterative arteriolopathy (suggesting primary endothelial damage), ischemic collapse or scarring of the glomeruli, vacuolization of the tubules, global and focal segmental glomerulosclerosis, and focal areas of tubular atrophy and interstitial fibrosis (producing a picture of "striped" fibrosis)  (
         <a class="graphic graphic_picture graphicRef75082 graphicRef54131 graphicRef70064" href="/z/d/graphic/75082.html" rel="external">
          picture 1A-C
         </a>
         ) [
         <a href="#rid1">
          1,3,5,44-47
         </a>
         ]. These changes are seen with both low-dose and higher-dose
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         therapy, although they seem to occur earlier with higher doses [
         <a href="#rid44">
          44,48,49
         </a>
         ].
        </p>
        <p>
         One histologic study reported the association of these changes with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         dose and over time [
         <a href="#rid50">
          50
         </a>
         ]. Mild arteriolar hyalinosis at six months appeared to be associated with high doses and was reversible. By comparison, at three years, irreversible severe arteriolar hyalinosis and glomerulosclerosis were observed, despite decreased doses and trough levels.
        </p>
        <p>
         The factors responsible for chronic CNI nephrotoxicity are not well understood. The development of interstitial fibrosis is associated with increased expression of osteopontin (a potent macrophage chemoattractant secreted by the tubular epithelial cells [
         <a href="#rid51">
          51
         </a>
         ]), chemokines (a class of cytokines that are strong chemoattractants for a variety of hematopoietic cells [
         <a href="#rid52">
          52
         </a>
         ]), and transforming growth factor (TGF)-beta (a powerful stimulator of extracellular matrix production [
         <a href="#rid53">
          53,54
         </a>
         ]).
        </p>
        <p>
         Support for a central role for TGF-beta has been provided by findings in mice in which
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         nephropathy was significantly diminished with anti-TGF-beta therapy [
         <a href="#rid55">
          55,56
         </a>
         ]. TGF-beta appears to be induced in part by decreased secretion of nitric oxide [
         <a href="#rid57">
          57
         </a>
         ] as well as increased local concentrations of angiotensin II, possibly explaining at least in part the beneficial effects observed with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists [
         <a href="#rid51">
          51,53,58
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         is a substrate for the transmembrane pump P-glycoprotein. There is some evidence in animals and in vitro that decreased expression of this pump may contribute to increased cyclosporine levels, leading to nephrotoxicity [
         <a href="#rid59">
          59,60
         </a>
         ]. Altered protein pump expression has also been observed in association with several polymorphisms in its gene. As an example, the TT genotype is associated with decreased P-glycoprotein expression in the kidney. In a case-control study of donor and recipient pairs, the TT genotype in the donor directly correlated with chronic cyclosporine nephrotoxicity in the allograft recipient (odds ratio [OR] 13.4, 95% CI 1.2-148) [
         <a href="#rid61">
          61
         </a>
         ]. This suggests that underlying genetic factors that increase cyclosporine concentrations in the kidney may contribute to chronic nephrotoxicity.
        </p>
        <p>
         It has been proposed that the arterial lesions are the primary abnormality, with secondary ischemia being responsible for the tubular and interstitial lesions. Some animal studies, for example, have shown that the vascular and interstitial findings can be dissociated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A report found that inhibiting angiotensin II with an ACE inhibitor or an angiotensin II receptor antagonist (
         <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">
          losartan
         </a>
         ) minimized the interstitial fibrosis without affecting the glomerular or tubular injury; this beneficial effect was not observed with the combination of
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         and
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study had somewhat different results [
         <a href="#rid51">
          51
         </a>
         ]. Both
         <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">
          losartan
         </a>
         and the combination of
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         and
         <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">
          furosemide
         </a>
         minimized interstitial fibrosis, while only losartan protected against the arteriolopathy.
        </p>
        <p>
        </p>
        <p>
         Increased apoptosis (ie, programmed cell death) occurs in kidneys exposed to
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ]. This finding may help explain the interstitial abnormalities associated with cyclosporine toxicity: the loss of cells and renal tubules accompanied by fibrosis. The expression of specific apoptotic genes, such as p53 and Fas ligand, is enhanced in rats administered cyclosporine, thereby favoring the induction of apoptosis [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2332016232">
         <span class="h1">
          CLINICAL PRESENTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calcineurin inhibitor (CNI) nephrotoxicity encompasses several different clinical manifestations that reflect functional and/or morphologic changes in the kidney allograft (in kidney transplant recipients) or the native kidney (in non-kidney solid organ transplant recipients or nontransplant patients). Acute CNI nephrotoxicity commonly presents as an acute but typically reversible functional kidney impairment and rarely as a thrombotic microangiopathy (TMA). Chronic CNI nephrotoxicity manifests as a chronic progressive deterioration in kidney function. In addition, CNIs have also been associated with a number of electrolyte and acid-base abnormalities that are a result of CNI-induced tubular dysfunction.
        </p>
        <p class="headingAnchor" id="H4250441904">
         <span class="h2">
          Acute reversible kidney injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         nephrotoxicity typically presents as an acute increase in plasma creatinine concentration, which is dose related and largely reversible after dose reduction or cessation of therapy [
         <a href="#rid40">
          40
         </a>
         ]. This reversible functional kidney impairment is primarily due to acute vasoconstriction of the afferent arterioles and resembles the clinical picture of prerenal disease (see
         <a class="local">
          'Acute calcineurin inhibitor nephrotoxicity'
         </a>
         above). The onset of acute CNI nephrotoxicity can occur anytime within hours to days to even years after CNI initiation. In kidney transplant recipients, acute CNI nephrotoxicity can also manifest as delayed recovery of function of a newly transplanted but malfunctioning allograft.
        </p>
        <p>
         Early studies of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         in kidney transplantation demonstrated a relationship between whole blood or plasma cyclosporine concentrations and acute CNI nephrotoxicity that was reversible with dose reduction [
         <a href="#rid25">
          25,64
         </a>
         ]. A similar dose relationship exists between
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         concentrations and nephrotoxicity [
         <a href="#rid26">
          26,65
         </a>
         ].
        </p>
        <p>
         In kidney transplant recipients, acute CNI nephrotoxicity may be difficult to differentiate from acute rejection. The only definitive diagnostic test is biopsy of the kidney allograft. Although there are no specific pathologic changes induced acutely by
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid3">
          3,66
         </a>
         ], the absence of acute T cell-mediated or antibody-mediated rejection as well as reversibility of kidney dysfunction with drug cessation (over days to a week) strongly suggest CNI nephrotoxicity. It is also important to appreciate that the presence of rejection does not exclude concomitant CNI toxicity. (See
         <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">
          "Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction", section on 'Evaluation of acute allograft dysfunction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">
          "Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1581632379">
         <span class="h2">
          Chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic CNI nephrotoxicity commonly presents as a chronic and progressive kidney function impairment due to glomerular and vascular disease, abnormalities in tubular function, and an increase in blood pressure [
         <a href="#rid2">
          2,15
         </a>
         ]. It is usually irreversible. Chronic CNI nephrotoxicity is thought to be caused by a combination of CNI-induced hemodynamic changes and toxic effects of CNIs on renal tubular epithelial cells. (See
         <a class="local">
          'Chronic calcineurin inhibitor nephrotoxicity'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7360.html" rel="external">
          "Hypertension after kidney transplantation", section on 'Immunosuppressive agents'
         </a>
         .)
        </p>
        <p>
         In kidney transplant recipients, chronic CNI nephrotoxicity may be difficult if not impossible to distinguish from chronic allograft nephropathy. (See
         <a class="medical medical_review" href="/z/d/html/7359.html" rel="external">
          "Kidney transplantation in adults: Chronic allograft nephropathy", section on 'Similar histologic findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H945349046">
         <span class="h2">
          Thrombotic microangiopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of CNIs has been associated with the development of de novo TMA after kidney transplantation. Patients typically present with a microangiopathic hemolytic anemia with schistocytes on the blood smear, thrombocytopenia, and acute kidney injury (AKI). The TMA associated with CNIs is presumably initiated by CNI-induced injury to the vascular endothelial cells. Concurrent use of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         with mammalian (mechanistic) target of rapamycin (mTOR) inhibitors has been shown to increase the risk of TMA [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         A more detailed discussion of TMA after kidney transplantation is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7350.html" rel="external">
          "Thrombotic microangiopathy after kidney transplantation", section on 'Clinical presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">
          "Drug-induced thrombotic microangiopathy (DITMA)", section on 'Immunosuppressive agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6575935">
         <span class="h2">
          Electrolyte and acid-base disturbances
         </span>
         <span class="headingEndMark">
          —
         </span>
         CNIs have been associated with the development of several electrolyte and metabolic abnormalities, including hyperkalemia, hyperuricemia and gout, metabolic acidosis, hypophosphatemia, hypomagnesemia, and hypercalciuria [
         <a href="#rid20">
          20,21,68,69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2147466755">
         <span class="h3">
          Hyperkalemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         An elevation in the plasma potassium concentration due to reduced efficiency of urinary potassium excretion is common in CNI-treated patients; it may be severe and potentially life-threatening with concurrent administration of an angiotensin-converting enzyme (ACE) inhibitor, which diminishes aldosterone release. CNIs may reduce potassium excretion both by decreasing the activity of the renin-angiotensin-aldosterone system and by impairing tubular responsiveness to aldosterone [
         <a href="#rid70">
          70,71
         </a>
         ].
        </p>
        <p>
         Urinary potassium excretion is primarily derived from potassium secretion in the collecting tubules via potassium channels in the luminal membrane  (
         <a class="graphic graphic_figure graphicRef60693" href="/z/d/graphic/60693.html" rel="external">
          figure 2
         </a>
         ). This process is stimulated by sodium reabsorption (which, unless chloride follows the sodium, creates a lumen-negative electrical gradient that promotes potassium secretion), aldosterone (which increases the number of open sodium channels in the luminal membrane), and the basolateral Na-K-ATPase pump (which removes reabsorbed sodium from the cell in exchange for potassium, thereby increasing the size of the potassium secretory pool). (See
         <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">
          "Causes of hypokalemia in adults", section on 'Increased urinary losses'
         </a>
         .)
        </p>
        <p>
         In vitro studies suggest that
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         may directly impair the function of the potassium-secreting cells in the cortical collecting tubule by affecting each of these steps: reduced activity of the Na-K-ATPase pump [
         <a href="#rid72">
          72
         </a>
         ], inhibition of the luminal potassium channel [
         <a href="#rid73">
          73
         </a>
         ], and increased chloride reabsorption, which prevents generation of lumen-negative potential, which drives potassium secretion [
         <a href="#rid71">
          71
         </a>
         ].
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          Tacrolimus
         </a>
         has been shown to have inhibitory effects on the Na-K-ATPase pump [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         may also have a second effect on potassium homeostasis in patients concurrently treated with a beta blocker. In this setting, there is often a modest (&lt;1 mEq/L) and transient elevation in the plasma potassium concentration due to the movement of potassium out of the cells, into the extracellular fluid [
         <a href="#rid75">
          75
         </a>
         ]. Why this occurs is not known.
        </p>
        <p>
         Issues surrounding the management of hyperkalemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2332.html" rel="external">
          "Treatment and prevention of hyperkalemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3679598527">
         <span class="h3">
          Metabolic acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tubular injury induced by
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         can also impair acid excretion. This may be manifested as a normal anion gap (hyperchloremic) metabolic acidosis that may also reflect decreased aldosterone activity and suppression of ammonium excretion by hyperkalemia [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2306.html" rel="external">
          "Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2536848049">
         <span class="h3">
          Hypophosphatemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         develop hypophosphatemia due to urinary phosphate wasting [
         <a href="#rid2">
          2,76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1824931879">
         <span class="h3">
          Hypomagnesemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Renal magnesium wasting is common in cyclosporine- and tacrolimus-treated recipients, presumably due to drug effects on magnesium reabsorption [
         <a href="#rid77">
          77-79
         </a>
         ]. Hypomagnesemia has been implicated as a contributor to the nephrotoxicity associated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid80">
          80
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/829.html" rel="external">
          "Hypomagnesemia: Causes of hypomagnesemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H792414565">
         <span class="h3">
          Hypercalciuria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         are associated with hypercalciuria [
         <a href="#rid79">
          79,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1643304903">
         <span class="h2">
          Hyperuricemia and gout
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         , via glomerular and tubular effects, can decrease urinary uric acid excretion, leading to hyperuricemia in most patients and occasionally symptomatic gout. (See
         <a class="medical medical_review" href="/z/d/html/7297.html" rel="external">
          "Kidney transplantation in adults: Hyperuricemia and gout in kidney transplant recipients"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          PREVENTION OF CHRONIC CALCINEURIN INHIBITOR NEPHROTOXICITY
         </span>
        </p>
        <p class="headingAnchor" id="H774212012">
         <span class="h2">
          Reduced exposure to calcineurin inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The replacement of calcineurin inhibitors (CNIs) with non-nephrotoxic immunosuppressive agents may ameliorate kidney dysfunction among patients with CNI nephrotoxicity. Benefits have been observed among kidney and non-kidney organ transplant recipients with decreased kidney function due to CNI therapy. Some studies, however, question whether CNI withdrawal is safe in those with adequate kidney function [
         <a href="#rid82">
          82
         </a>
         ]. A detailed discussion related to CNI withdrawal in kidney allograft recipients is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7359.html" rel="external">
          "Kidney transplantation in adults: Chronic allograft nephropathy", section on 'Reducing calcineurin inhibitor exposure'
         </a>
         .)
        </p>
        <p>
         Whether there is a "safe" chronic dose of a CNI that is effective immunologically, but does not cause progressive kidney dysfunction, is difficult to answer because of the lack of well-controlled prospective trials. (See
         <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">
          "Kidney transplantation in adults: Maintenance immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
         Short-term studies suggest that low doses of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         may not lead to kidney dysfunction [
         <a href="#rid11">
          11,82,83
         </a>
         ]. As an example, the Cyclosporine Avoidance Eliminates Serious Adverse Renal-toxicity (CAESAR) study found similar kidney function at one year among a group of 536 first-time kidney transplant recipients randomly assigned to low-dose cyclosporine (target trough level of 50 to 100 ng/mL), low-dose cyclosporine and cyclosporine withdrawal at six months, and standard-dose cyclosporine therapy (first four months at 150 to 300 ng/mL target trough level and 100 to 200 ng/mL thereafter) [
         <a href="#rid82">
          82
         </a>
         ]. In addition, although acute rejection was similar at six months, at approximately 25 percent, it was significantly higher at one year in the cyclosporine withdrawal group, with a one-year rejection rate of 38 percent.
        </p>
        <p>
         Overall, however, there is a strong association between chronic kidney allograft dysfunction and long-term continuous exposure to maintenance doses of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         [
         <a href="#rid4">
          4,50,84,85
         </a>
         ]. Perhaps the best insight into the time dependence of chronic CNI nephrotoxicity was provided by a study of 120 kidney-pancreas recipients who underwent sequential kidney protocol biopsies over a 10-year posttransplantation period [
         <a href="#rid84">
          84
         </a>
         ]. Triple-agent immunosuppressive therapy consisting of cyclosporine/tacrolimus,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         /
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil was administered.
        </p>
        <p>
         Early damage, which was observed within one year posttransplantation, resulted primarily from immunologic factors such as severe acute rejection and persistent early subclinical rejection, as well as from ischemic injury. By comparison, after one year posttransplant, damage was characterized by progressive high-grade arteriolar hyalinosis, with vessel narrowing, glomerulosclerosis, and additional tubulointerstitial injury. This was thought to principally be the result of CNI injury. By comparison, chronic immune rejection was uncommon with prolonged follow-up. At 10 years, severe allograft nephropathy was present in 60 percent of patients, with glomerulosclerosis being observed in almost 40 percent of glomeruli. (See
         <a class="medical medical_review" href="/z/d/html/7359.html" rel="external">
          "Kidney transplantation in adults: Chronic allograft nephropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3422584165">
         <span class="h2">
          Other approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         In view of the utility of CNIs in transplantation and autoimmune diseases, there has been a great deal of interest in developing therapeutic strategies to minimize their nephrotoxic effects. Although multiple agents have been evaluated, including cold water fish oil, calcium channel blockers, thromboxane synthesis inhibitors, and
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         , none is clearly effective.
        </p>
        <p class="headingAnchor" id="H1515806287">
         <span class="h3">
          Therapies with unclear benefit
         </span>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h4">
          Fish oil
         </span>
         <span class="headingEndMark">
          —
         </span>
         The fish oils, which contain omega-3 fatty acids, may act by competitively reducing thromboxane synthesis, thereby diminishing cyclosporine-induced vasoconstriction and hypertension, and by direct immunosuppressive actions, such as decreasing the generation of cytokines [
         <a href="#rid86">
          86
         </a>
         ]. Swallowing problems, a fishy aftertaste, and impaired hemostasis are potential complications.
        </p>
        <p>
         To assess the efficacy of fish oil in kidney transplantation, a systematic review and meta-analysis published in 2005 were performed of 16 studies enrolling a total of 812 patients [
         <a href="#rid87">
          87
         </a>
         ].
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         was used in combination with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         in all but one study, which evaluated cyclosporine alone. Among the 11 trials reporting effects on glomerular filtration rate (GFR), there was no consistent benefit of fish oil on kidney function, with only a modest benefit being reported in a few studies [
         <a href="#rid86">
          86,88-90
         </a>
         ]. Meta-analyses also found no survival benefit or decreased incidence of rejection with fish oil. Similar findings were noted in two subsequent meta-analyses that largely analyzed the same studies [
         <a href="#rid91">
          91,92
         </a>
         ]. These data suggest that fish oil is not associated with a consistent clinical benefit.
        </p>
        <p>
         The long-term administration of arginine and canola oil, which contain both omega-3 and -9 fatty acids, was associated with a decreased incidence of CNI drug toxicity in a randomized, prospective, three-year study of 78 kidney allograft recipients (9 versus 35 percent in controls) [
         <a href="#rid93">
          93
         </a>
         ]. Additional benefits with this diet, as noted in this study, included decreased incidence of first rejection episodes, posttransplant diabetes, and cardiovascular events. However, a longer-term evaluation in a larger number of patients is required to better understand the role for this diet, particularly given that a large number of patients stopped taking or were noncompliant with the agent.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h4">
          Calcium channel blockers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Animal and human data suggest that concurrent administration of calcium channel blockers may be protective against
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         nephrotoxicity, at least in part by minimizing renal vasoconstriction [
         <a href="#rid94">
          94
         </a>
         ]. However, there is at present no proof that these agents increase graft survival [
         <a href="#rid95">
          95,96
         </a>
         ]. In one report, for example, 113 cyclosporine-treated patients were randomly assigned to
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         or placebo after kidney transplantation [
         <a href="#rid95">
          95
         </a>
         ]. At two years, there was no difference between the groups in blood pressure, plasma creatinine concentration, the number of rejection episodes, or the frequency of graft loss. The patients treated with diltiazem did have a lower incidence of primary nonfunction and fewer episodes of severe rejection, particularly vascular rejection; they also required 35 percent less cyclosporine due to the diltiazem-induced slowing of cyclosporine metabolism.
        </p>
        <p>
         A similar lack of benefit on long-term kidney function has been noted with
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         in two studies of hypertensive transplant recipients receiving
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         : One prospectively compared nifedipine with the angiotensin-converting enzyme (ACE) inhibitor
         <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">
          lisinopril
         </a>
         , and one retrospectively compared nifedipine with treatment without a calcium channel blocker [
         <a href="#rid97">
          97,98
         </a>
         ]. Neither study was able to demonstrate a better outcome with nifedipine in terms of blood pressure control, the directly measured GFR, or the plasma creatinine concentration at two to five years.
        </p>
        <p>
         However, it is possible that some calcium channel blockers may have a small protective effect on the kidney [
         <a href="#rid99">
          99,100
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study randomly assigned 109 normotensive kidney transplant recipients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         to placebo or nitrendipine (5 mg two-times daily) and 146 hypertensive transplant patients to placebo or nitrendipine (10 mg two-times daily) [
         <a href="#rid99">
          99
         </a>
         ]. Among all individuals at two years or at the time of study withdrawal, active therapy was associated with a slightly but significantly lower serum creatinine concentration (1.68 versus 1.80 mg/dL [149 versus 161 micromol/L]). This effect was statistically significant only among the hypertensive patients, but the small benefit was independent of any antihypertensive effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a multicenter study, 131 kidney transplant recipients being administered
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         were randomly assigned to lacidipine or placebo [
         <a href="#rid100">
          100
         </a>
         ]. Allograft function was significantly better with the calcium channel blocker at one and two years posttransplant (50 versus 43 mL/min/1.73 m
         <sup>
          2
         </sup>
         and 50 versus 42 mL/min/1.72 m
         <sup>
          2
         </sup>
         at year 1 and 2, respectively).
        </p>
        <p>
        </p>
        <p>
         One possible explanation for the conflicting results demonstrating a long-term benefit with calcium channel blockers in patients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         is that renal vasoconstriction may not be responsible for the chronic vascular and tubulointerstitial injury. This hypothesis is supported by observations in animals showing that administration of an endothelin A receptor antagonist minimized the fall in GFR and renal plasma flow but had no effect on the arteriolopathy or tubular damage [
         <a href="#rid101">
          101
         </a>
         ]. Alternatively, the inability to demonstrate a better outcome with a calcium channel blocker versus an ACE inhibitor may result from inhibition of angiotensin II activity also protecting against kidney injury, although by a different mechanism [
         <a href="#rid51">
          51,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7359.html" rel="external">
          "Kidney transplantation in adults: Chronic allograft nephropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3835629091">
         <span class="h4">
          Renin-angiotensin system inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the role of renin-angiotensin system (RAS) activation in the pathogenesis of CNI nephrotoxicity (see
         <a class="local">
          'Chronic calcineurin inhibitor nephrotoxicity'
         </a>
         above), RAS inhibition has been proposed as a potential strategy to prevent its development. Although studies in animals have shown that ACE inhibitors and angiotensin receptor blockers (ARBs) can prevent cyclosporine-induced interstitial fibrosis and improve kidney function [
         <a href="#rid102">
          102-104
         </a>
         ], studies in humans have not demonstrated a clear benefit:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one small trial, 24 patients with recent-onset insulin-dependent diabetes mellitus with no prior kidney involvement were randomly assigned to receive a three-month course of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         alone or cyclosporine plus
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         [
         <a href="#rid105">
          105
         </a>
         ]. At three months, GFR remained unchanged in those treated with cyclosporine and enalapril but decreased by 17 percent in patients treated with cyclosporine alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another small trial compared the effects of
         <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">
          lisinopril
         </a>
         versus
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         in 25 kidney transplant recipients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid97">
          97
         </a>
         ]. Kidney function was similar in both groups at baseline. At approximately 1 and 2.5 years, there was no change in GFR in each group compared with baseline, suggesting that each drug provided a similar degree of kidney protection. However, in a larger randomized trial comparing nifedipine and lisinopril in kidney transplant patients treated with cyclosporine, an improvement in graft function at two years posttreatment occurred in those treated with nifedipine but not those treated with lisinopril [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Studies in animals suggest a possible protective benefit to treatment with an aldosterone antagonist (eg,
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         ) [
         <a href="#rid107">
          107-111
         </a>
         ] although kidney benefits have not been shown in humans [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2514718790">
         <span class="h3">
          Therapies with no benefit
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pentoxifylline
         </strong>
         <strong>
         </strong>
         – Attenuation of cyclosporine-induced renal vasoconstriction and nephrotoxicity in animal studies with
         <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">
          pentoxifylline
         </a>
         prompted a randomized trial evaluating the effect of this agent in cardiac transplant recipients [
         <a href="#rid113">
          113
         </a>
         ]. Twenty-nine patients received either pentoxifylline (400 mg three-times daily) or placebo for one year. No difference was observed in GFR or plasma creatinine concentration between the two groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thromboxane synthesis inhibitor
         </strong>
         – A proposed role for thromboxane in cyclosporine-induced renal vasoconstriction has led to the evaluation of thromboxane synthesis inhibitors. In one report, a thromboxane synthesis inhibitor was given for four weeks to stable patients with a low GFR of 45 mL/min that was presumed to reflect
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         nephrotoxicity [
         <a href="#rid114">
          114
         </a>
         ]. Despite an 80 to 90 percent reduction in the excretion of thromboxane metabolites, there was no improvement in either GFR or renal blood flow.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H122017">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Patients treated with the calcineurin inhibitors (CNIs)
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         are at high risk of developing kidney injury. Most data on CNI nephrotoxicity pertain to cyclosporine since it has been used for a much longer time. However, a similar pattern of kidney injury from cyclosporine is seen with the use of tacrolimus, thereby suggesting a drug class effect. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors
         </strong>
         – Several factors may contribute to the risk of CNI nephrotoxicity, including high doses of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ; older age of donated kidney; concomitant use of nephrotoxic drugs, particularly nonsteroidal antiinflammatory drugs (NSAIDs); salt depletion and diuretic use; drugs that inhibit cytochrome P-450 3A4/5 (CYP3A/5) or P-glycoprotein; and genetic polymorphisms in the genes encoding CYP3A4/5 (
         <em>
          CYP3A4/5
         </em>
         ) and P-glycoprotein (
         <em>
          ABCB1
         </em>
         ). (See
         <a class="local">
          'Risk factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentations
         </strong>
         – CNI nephrotoxicity encompasses several different clinical manifestations that reflect functional and/or morphologic changes in the kidney allograft (in kidney transplant recipients) or the native kidney (in non-kidney solid organ transplant recipients or nontransplant patients). Acute CNI nephrotoxicity commonly presents as an acute but typically reversible kidney function impairment and rarely as a thrombotic microangiopathy (TMA). Chronic CNI nephrotoxicity manifests as a chronic progressive deterioration in kidney function. In addition, CNIs have also been associated with a number of electrolyte and acid-base abnormalities that are a result of CNI-induced tubular dysfunction. (See
         <a class="local">
          'Clinical presentations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of chronic nephrotoxicity
         </strong>
         – The replacement of CNIs with non-nephrotoxic immunosuppressive agents may ameliorate kidney function impairment among patients with CNI nephrotoxicity. Benefits have been observed among kidney and non-kidney organ transplant recipients with decreased kidney function due to CNI therapy. Some studies, however, question whether CNI withdrawal is safe in those with adequate kidney function. A number of agents have been evaluated to help prevent chronic CNI nephrotoxicity, but none are clearly effective. (See
         <a class="local">
          'Prevention of chronic calcineurin inhibitor nephrotoxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2409957095">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges William M Bennett, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23:465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1990; 1:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liquete E, Williamson SR, Janakiraman N, Venkat KK. Renal Complications of Hematopoietic Stem Cell Transplantation: Report of a Case and Review of the Literature. Indian J Nephrol 2017; 27:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillebout E, Nochy D, Hill G, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005; 5:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lachance K, White M, de Denus S. Risk Factors for Chronic Renal Insufficiency Following Cardiac Transplantation. Ann Transplant 2015; 20:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smail N, Paraskevas S, Tan X, et al. Renal function in recipients of pancreas transplant alone. Curr Opin Organ Transplant 2012; 17:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloom RD, Reese PP. Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007; 18:3031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Novick AC, Hwei HH, Steinmuller D, et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation 1986; 42:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 1997; 63:664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frimat L, Villemot JP, Cormier L, et al. Treatment of end-stage renal failure after heart transplantation. Nephrol Dial Transplant 1998; 13:2905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams D, Haragsim L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 2006; 13:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shihab FS, Waid TH, Conti DJ, et al. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. Transplantation 2008; 85:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nankivell BJ, PʼNg CH, OʼConnell PJ, Chapman JR. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. Transplantation 2016; 100:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9:1876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:1110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porayko MK, Textor SC, Krom RA, et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994; 69:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klintmalm G, Bohman SO, Sundelin B, Wilczek H. Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period. Lancet 1984; 2:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henny FC, Kleinbloesem CH, Moolenaar AJ, et al. Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. Transplantation 1985; 40:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laskow DA, Vincenti F, Neylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Remuzzi G, Cravedi P, Perna A, et al. Long-term outcome of renal transplantation from older donors. N Engl J Med 2006; 354:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovarik JM, Kurki P, Mueller E, et al. Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. J Rheumatol 1996; 23:2033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soubhia RM, Mendes GE, Mendonça FZ, et al. Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided. Am J Nephrol 2005; 25:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74:1486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008; 18:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xia T, Zhu S, Wen Y, et al. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis. Drug Des Devel Ther 2018; 12:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91:2144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Nicola L, Thomson SC, Wead LM, et al. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 1993; 92:1859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamas S. Cellular mechanisms of vascular injury mediated by calcineurin inhibitors. Kidney Int 2005; 68:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherrer U, Vissing SF, Morgan BJ, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wissmann C, Frey FJ, Ferrari P, Uehlinger DE. Acute cyclosporine-induced nephrotoxicity in renal transplant recipients: the role of the transplanted kidney. J Am Soc Nephrol 1996; 7:2677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. National High Blood Pressure Education Program. Arch Intern Med 1990; 150:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrol 1991; 2:S45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sis B, Dadras F, Khoshjou F, et al. Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. Am J Transplant 2006; 6:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kambham N, Nagarajan S, Shah S, et al. A novel, semiquantitative, clinically correlated calcineurin inhibitor toxicity score for renal allograft biopsies. Clin J Am Soc Nephrol 2007; 2:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           di Paolo S, Teutonico A, Stallone G, et al. Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients. Nephrol Dial Transplant 2004; 19:2107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman JR, Nankivell BJ. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? Nephrol Dial Transplant 2006; 21:2060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichler RH, Franceschini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shihab FS, Bennett WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Islam M, Burke JF Jr, McGowan TA, et al. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 2001; 59:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling H, Li X, Jha S, et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003; 14:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xin J, Homma T, Matsusaka T, et al. Suppression of cyclosporine a nephrotoxicity in vivo by transforming growth factor beta receptor-immunoglobulin G chimeric protein. Transplantation 2004; 77:1433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58:1174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269:F491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Moral RG, Olmo A, Osuna A, et al. Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits. Transplant Proc 1998; 30:2014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koziolek MJ, Riess R, Geiger H, et al. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001; 60:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shihab FS, Andoh TF, Tanner AM, et al. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 1999; 56:2147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klintmalm G, Säwe J, Ringdén O, et al. Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection. Transplantation 1985; 39:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortin MC, Raymond MA, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 2004; 4:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerster JC, Dudler M, Halkic N, Gillet M. Gout in liver transplant patients receiving tacrolimus. Ann Rheum Dis 2004; 63:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holman MJ, Gonwa TA, Cooper B, et al. FK506-associated thrombotic thrombocytopenic purpura. Transplantation 1993; 55:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deray G, Benhmida M, Le Hoang P, et al. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992; 117:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamel KS, Ethier JH, Quaggin S, et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1992; 2:1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tumlin JA, Sands JM. Nephron segment-specific inhibition of Na+/K(+)-ATPase activity by cyclosporin A. Kidney Int 1993; 43:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ling BN, Eaton DC. Cyclosporin A inhibits apical secretory K+ channels in rabbit cortical collecting tubule principal cells. Kidney Int 1993; 44:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lea JP, Sands JM, McMahon SJ, Tumlin JA. Evidence that the inhibition of Na+/K(+)-ATPase activity by FK506 involves calcineurin. Kidney Int 1994; 46:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pei Y, Richardson R, Greenwood C, et al. Extrarenal effect of cyclosporine A on potassium homeostasis in renal transplant recipients. Am J Kidney Dis 1993; 22:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moz Y, Levi R, Lavi-Moshayoff V, et al. Calcineurin Abeta is central to the expression of the renal type II Na/Pi co-transporter gene and to the regulation of renal phosphate transport. J Am Soc Nephrol 2004; 15:2972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           al-Khursany I, Thomas TH, Harrison K, Wilkinson R. Reduced erythrocyte and leukocyte magnesium is associated with cyclosporin treatment and hypertension in renal transplant patients. Nephrol Dial Transplant 1992; 7:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton CH, Vaziri ND, Martin DC, et al. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med 1987; 83:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nijenhuis T, Hoenderop JG, Bindels RJ. Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 2004; 15:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miura K, Nakatani T, Asai T, et al. Role of hypomagnesemia in chronic cyclosporine nephropathy. Transplantation 2002; 73:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CT, Huynh VM, Lai LW, Lien YH. Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice. Kidney Int 2002; 62:2055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tostivint I, du Montcel ST, Jaudon MC, et al. Renal outcome after ciclosporin-induced nephrotoxicity. Nephrol Dial Transplant 2007; 22:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyer O, Le Bidois J, Dechaux M, et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005; 79:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Heide JJ, Bilo HJ, Donker JM, et al. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 1993; 329:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatsioni A, Chung M, Sun Y, et al. Effects of fish oil supplementation on kidney transplantation: a systematic review and meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2005; 16:2462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berthoux FC, Guerin C, Burgard G, et al. One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation. Transplant Proc 1992; 24:2578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homan van der Heide JJ, Bilo HJ, Tegzess AM, Donker AJ. The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients. Transplantation 1990; 49:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maachi K, Berthoux P, Burgard G, et al. Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy. Transplant Proc 1995; 27:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim AK, Manley KJ, Roberts MA, Fraenkel MB. Fish oil treatment for kidney transplant recipients: a meta-analysis of randomized controlled trials. Transplantation 2007; 83:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim AK, Manley KJ, Roberts MA, Fraenkel MB. Fish oil for kidney transplant recipients. Cochrane Database Syst Rev 2016; :CD005282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander JW, Metze TJ, McIntosh MJ, et al. The influence of immunomodulatory diets on transplant success and complications. Transplantation 2005; 79:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer BF, Dawidson I, Sagalowsky A, et al. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991; 52:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladefoged SD, Pedersen E, Hammer M, et al. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 1994; 9:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponticelli C, Montagnino G, Aroldi A, et al. Hypertension after renal transplantation. Am J Kidney Dis 1993; 21:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahn KH, Barenbrock M, Fritschka E, et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354:1415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuypers DR, Neumayer HH, Fritsche L, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunley TE, Fogo A, Iwasaki S, Kon V. Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 1995; 5:1718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mervaala E, Lassila M, Vaskonen T, et al. Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet. Blood Press 1999; 8:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li C, Sun BK, Lim SW, et al. Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. Transplantation 2005; 79:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun BK, Li C, Lim SW, et al. Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity. Nephron Exp Nephrol 2005; 99:e9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannedouche TP, Natov S, Boitard C, et al. Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes. Nephrol Dial Transplant 1996; 11:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72:1787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feria I, Pichardo I, Juárez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-Rojas JM, Derive S, Blanco JA, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005; 289:F1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen FT, Jensen BL, Marcussen N, et al. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. Nephrol Dial Transplant 2008; 23:2777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macunluoglu B, Arikan H, Atakan A, et al. Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. Transplant Proc 2008; 40:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bobadilla NA, Gamba G. New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007; 293:F2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortensen LA, Thiesson HC, Tougaard B, et al. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial). BMC Nephrol 2018; 19:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frantz RP, Edwards BS, Olson LJ, et al. Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: a randomized trial. Transplantation 1997; 63:1607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith SR, Kubacki VB, Rakhit A, et al. Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity. Transplantation 1993; 56:1422.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7357 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13680536" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cyclosporine nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2687689" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2104260" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cellular and molecular mechanisms of cyclosporin nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10676738" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19218475" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Calcineurin inhibitor nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29217887" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Renal Complications of Hematopoietic Stem Cell Transplantation: Report of a Case and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15816895" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Renal histopathological lesions after orthotopic liver transplantation (OLT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26417876" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Risk Factors for Chronic Renal Insufficiency Following Cardiac Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22186098" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Renal function in recipients of pancreas transplant alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18039925" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Chronic kidney disease after nonrenal solid-organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3526655" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12954741" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chronic renal failure after transplantation of a nonrenal organ.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9075835" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9829499" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Treatment of end-stage renal failure after heart transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16412970" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Calcineurin nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18094377" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Reduced exposure to calcineurin inhibitors in renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18475181" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27306529" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19563339" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7523946" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7520105" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7508536" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15816894" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6149343" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3898491" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8878381" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436766" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Long-term outcome of renal transplantation from older donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970037" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15976495" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11279519" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12490779" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12966368" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15502717" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18704002" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17495880" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29535503" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8486781" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8408638" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Arginine feeding modifies cyclosporine nephrotoxicity in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8455370" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16014073" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cellular mechanisms of vascular injury mediated by calcineurin inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2388667" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cyclosporine-induced sympathetic activation and hypertension after heart transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8989748" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Acute cyclosporine-induced nephrotoxicity in renal transplant recipients: the role of the transplanted kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2405801" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cyclosporine-associated hypertension. National High Blood Pressure Education Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1932643" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1942772" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16686769" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699397" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A novel, semiquantitative, clinically correlated calcineurin inhibitor toxicity score for renal allograft biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15187199" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16728428" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15446315" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8589285" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9987092" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9291185" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11168932" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12538738" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15167603" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Suppression of cyclosporine a nephrotoxicity in vivo by transforming growth factor beta receptor-immunoglobulin G chimeric protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10972680" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7485533" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9723372" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11422747" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15772250" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9551396" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10594790" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3881851" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8878385" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3291311" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Histopathology of cyclosporine nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15147429" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15194597" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Gout in liver transplant patients receiving tacrolimus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7678357" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : FK506-associated thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1524331" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1627752" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8381891" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Nephron segment-specific inhibition of Na+/K(+)-ATPase activity by cyclosporin A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8264157" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cyclosporin A inhibits apical secretory K+ channels in rabbit cortical collecting tubule principal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7527873" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Evidence that the inhibition of Na+/K(+)-ATPase activity by FK506 involves calcineurin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8352259" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Extrarenal effect of cyclosporine A on potassium homeostasis in renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579499" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Calcineurin Abeta is central to the expression of the renal type II Na/Pi co-transporter gene and to the regulation of renal phosphate transport.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1314999" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Reduced erythrocyte and leukocyte magnesium is associated with cyclosporin treatment and hypertension in renal transplant patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3314493" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14978156" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11884928" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Role of hypomagnesemia in chronic cyclosporine nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12427129" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17229079" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17127700" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Renal outcome after ciclosporin-induced nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14668458" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The natural history of chronic allograft nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15912111" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8350886" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15958723" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Effects of fish oil supplementation on kidney transplantation: a systematic review and meta-analysis of randomized, controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1465872" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2316014" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7879202" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17460552" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Fish oil treatment for kidney transplant recipients: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27535773" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Fish oil for kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15729173" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The influence of immunomodulatory diets on transplant success and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1926343" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Improved outcome of cadaveric renal transplantation due to calcium channel blockers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8434380" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Diltiazem in renal allograft recipients receiving cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8090335" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8382753" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8494023" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Hypertension after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10543667" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15502721" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7780063" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10412883" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15940041" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15637465" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8671857" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Angiotensin converting enzyme inhibition and chronic cyclosporine-induced renal dysfunction in type 1 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11740389" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12472767" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15998842" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18424460" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18261605" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17429034" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29724188" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9197354" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8279014" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Chronic thromboxane synthase inhibition with CGS 12970 in human cyclosporine nephrotoxicity.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
